Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.

Sarah BouchereauLouise ChaplainMagali FortAlain BeauchetThomas SidibéMarie ChapalainLeire Gonzalez-LaraChristine LongvertAstrid BlomPhilippe SaiagElisa Funck-Brentano

Published in: British journal of cancer (2021)

Dacarbazine seems to offer a short-lived benefit in patients with progressive advanced disease despite ICI (±targeted therapy), and could be an alternative before considering best supportive care.

Keyphrases

healthcare
multiple sclerosis
quality improvement
pain management
combination therapy
chronic pain
affordable care act
health insurance